Digital Information Services
Membership | FAQ | About | Contact | Home 
Indonesia Companies Indonesia Contact Persons Indonesia Tariffs and Trade
Industry Market Research and Reports Global Industry Market Research Industry Market Research
Search databases
UsernamePassword

Phapros Tbk., PT

info@disb2b.com Live Support What's my password?
 

Related Reports

Company News
Phapros’ Partnership Fund Rp.1.8 Billion
Bisnis Indonesia,, 2005-01-06
This year, PT Phapros Tbk will allocate a loan worth Rp.1.8 billion for the partnership programme with small businesses and cooperatives. The interest will vary from 6 percent to 12 percent per year from income. The payments could be done in 24 months. For the past 8 years, Phapros has recorded in loaning similar type loans to small businesses and cooperatives worth a total of Rp.3.4 billion. Up to this point, only Rp.200 million worth in payment is having trouble being returned.
Phapros Develops Herbal Medicine
www.suaramerdeka.com, 2004-03-27
Due to high prices of raw materials for chemical medicines, PT Phapros has started to develop herbal medicine for the regional market. Since 90 percent of the raw material for chemical medicines have to be imported, manufacturing herbal medicines, which have lower side effect, is a much feasible option. Phapros started producing herbal medicines under the name of Agromed in 2001. Phapros, one of the largest pharmaceutical companies in Indonesia, has co-operated with a number of domestic vendours to provide raw materials for herbal medicines and produce these medicines in accordance to modern standards and quality. The system has helped expand other business networks and also develop Indonesia’s potential as medicinal plants’ developer. Phapros products, Tensigard and X-gra, have acquired phytopharmaceutical registration and are two of the four drugs that passed the registration. The management has prepared a Rp.30 billion budget to improve production, research and human resource development facilities. In 2003, Phapros had a 44 percent growth, which was higher than the average growth of the pharmaceutical industry (13.5 percent).

Copyright & Disclaimer
PT. Dataindo Inti Swakarsa makes no representation to any other person with regard to the completeness or accuracy of the data or information contained herein, and it accepts no responsibility and disclaims all liability (save for liability which cannot be lawfully disclaimed) for loss or damage whatsoever suffered or incurred by any other person resulting from the use of, or reliance upon, the features, functions, tools, data or information contained herein.Information provided is not financial product advice. This report contains general information only. It is not intended as financial product advice and must not be relied upon as such. You should consider obtaining independent advice tailored to your specific circumstances before making any financial decisions. Copyright in this publication is owned by PT. Dataindo Inti Swakarsa. The publication is sold on the basis that the purchaser agrees not to copy the material contained within it for other than the purchasers own purposes. In the event that the purchaser uses or quotes from the material in this publication - in papers, reports, or opinions prepared for any other person - it is agreed that it will be sourced to: PT. Dataindo Inti Swakarsa

Phapros Tbk., PT
Indonesia Company Report
Last Update 19-June-2013
Major Businessline : Pharmaceutical

PT. Dataindo Inti SwakarsaTelp : (62 - 21) 719 3832
3rd Floor, Gapura Raya BuildingTelp : (62 - 21) 719 3834
Jl. Bangka Raya No. 4, Pela Mampang Email : dis@diswebpage.com
Jakarta 12720, Indonesia
Selective Member’s Information US $ Select
Address 0.00
Telephone number(s) [1] 0.15
Facsimile number(s) [2] 0.60
Website 0.15
Personnel (Commissioner [4], Director [3]) 2.45
Establishment Date 0.60
Business Activity 0.30
Legality (Ownership Type) 0.25
Number of employees 0.55
Certification(s) [2] 0.50
Brands / Trade Mark 0.55
Authorised Capital [28-Aug-12] 2.50
Paid Up Capital [28-Aug-12] 2.50
Auditor(s) [1] [23-Jul-09] 1.00
Shareholder(s) [1] 2.50
Number Of Shares 2.50
Share Nominal Value 2.50
Additional Information [24-Aug-10] 0.50
Profit and Loss [2008,2009,2010,2011,2012]
(Net Sales, Cost of Goods Sold, Gross Profit, Operating Expense, Operating Profit (Loss), Other Income (Expense), Profit (Loss) After Tax, Growth)
Balance Sheet [2008,2009,2010,2011,2012]
(Total Assets, Current Assets, Non Current Assets, Other Assets, Total Liabilities, Current Liabilities, Long Term Liabilities, Minority, Shareholder's Equity)
5.00
Ratios (Times) & Per Share Data [2008,2009,2010,2011,2012]
(PER, PBV, Current Ratio, Debt to Equity, Leverage, Gross Profit Margin, Operating Profit Margin, Net Profit Margin, Inventory Turnover, Total Assets Turnover, ROI, ROE)
0.50
TOTAL PRICE (US$)(RP)
Price 50.00570.000
Payment Method
Credit Card
Bank Transfer in US$
Bank Transfer in RP
Buy Now

 
Selective Member`s Discount Price
US$
To become a Selective Member
Register
Report Content
PROFIT AND LOSS 2005 2006 2007
Revenue 13,613,840 13,229,085 15,397,484
Cost of Goods N/A N/A N/A
Gross Profit 13,613,840 13,229,085 15,397,484
Net Profit Before Tax 3,139,711 4,528,733 5,123,618
The data above is sample data only
Balance Sheet (In RP Millions) 2005 2006 2007
Total Assets 133,260,087 149,168,842 150,180,752
Non Current Assets 1,888,511 1,935,151 2,024,748
Other Assets 2,885,953 4,075,426 50,103,265
Cash on Hand in Bank 47,751,808 43,551,174 27,213,874
Placement in other Bank 3,697,885 2,558,909 7,344,934
Notes & Securities 48,516,569 57,691,639 10,714,256
Loans 28,329,341 39,280,369 52,778,750
Total Liabilities 120,634,642 135,243,441 134,333,598
Cash
Minority 776 990 1,268
Total Deposits 118,251,011 131,985,222 129,555,406
Call Money 796,988 672,224 720,321
Notes Issued 252,202 425,039 652,439
Borrowings 219,652 484,127 525,316
Other Liabilities 1,114,013 1,675,839 2,878,848
Shareholder"s Equity 12,625,445 13,925,401 15,847,154
The data above is sample data only